AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 04/16/24

Novel 505(b)(2) presentation of a key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma, does not require reconstitution, dilution, or refrigeration Amneal plans to launch two to three branded oncology 505(b)(2) products per year going forw...

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its first quarter 2024 financial results on Friday, May 3, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. Th...

2024-04-08 15:32:37 ET More on Bausch Health Companies Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation Bausch Health Companies (BHC) Q4 2023 Earnings Call Transcript Bausch Health sues Amneal Pharma over Xifaxan generic Bausch Health Com...

2024-04-06 09:26:54 ET More on Amneal, Bausch Health, etc. Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Bausch Health: A Timely Divestiture Is The Key To An Higher Val...

- Celebrating Amneal’s recent listing on the Nasdaq Stock Exchange Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, today announced that Chirag and Chintu Patel, Co-founders and Co-Chief Execut...

2024-03-25 17:15:09 ET Gainers: Stoke Therapeutics ( STOK ) +87% . AnaptysBio ( ANAB ) +8% . Amneal Pharmaceuticals ( AMRX ) +6% . Omega Therapeutics ( OMGA ) +5% . MoneyHero  ( MNY ) +5% . Losers: Ocular Therapeutix...

- Product references branded Ciprodex - Represents another complex, high value new product Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (“ANDA”) ...

2024-03-01 07:27:26 ET DENVER, Colo., Mar 01, 2024 ( 247marketnews.com )- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX ) reported its fourth quarter and full year 2023 financial results, this morning. Its full year 2023 net revenue was $2.39 billion and projects 2024 financial gui...

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced that it has entered into an exclusive licensing agreement with Zambon Biotech SA, part of the Zambon group (“Zambon”), for IPX203 in the European Union, United Kingdom...

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer, will participate in the following investor conference. Barclays 26th Annual Global Healthcare Conference March 13, 2024 Miami, FL Fireside chat – 8:30 AM ET One-on-one...